Inspection Record

Vita Pharmacy, LLC dba Talon Pharmacy of Boerne — FDA 483 Findings

US FDAInspected 2021-11-02Published 2022-02-04 6 findingsValidation and qualificationAseptic processing and sterility assuranceEquipment and facilityCleaning validationOther quality system

View the regulator's official source The source document is always the basis for judgement.

Findings

1Validation and qualification

The certification of the ISO 5 areas was inadequate.

2Aseptic processing and sterility assurance

Media fills are not performed that closely simulate aseptic production operations, incorporating, as appropriate, worst case activities and conditions that provide a challenge to aseptic operations.

3Equipment and facility

Your facility design may allow the influx of poor quality air into a higher classified area.

4Cleaning validation

On 10/27/2021, I observed a dark residue on the plastic grille enclosing the HEPA filter located in the ISO 5 workbench area.

5Aseptic processing and sterility assurance

Materials and supplies were not disinfected prior to entering the aseptic processing areas.

6Other quality system

You produced hazardous drugs without providing adequate containment and segregation to prevent cros s­contammation.

About this record

Extracted automatically from the document US FDA published on 2022-02-04. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Vita Pharmacy, LLC dba Talon Pharmacy of Boerne company profile — full history US FDA documents, 2022 Go to Findings search